Uncategorized

Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option

Published

1 day ago

on

New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the liver. Vivatides’ investors include …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version